戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  many different interactions (for example in pharmaceutical research).
2  a valuable tool in thiol-related biomedical/pharmaceutical research.
3 cs with heteroaromatic azoles of interest in pharmaceutical research.
4  coefficient (D) is a crucial measurement in pharmaceutical research.
5 portant large animal model in biomedical and pharmaceutical research.
6 behind these complex phenomena is crucial in pharmaceutical research.
7 arity measures to identify new compounds for pharmaceutical research.
8 or siRNAs is a mainstay of both academic and pharmaceutical research.
9 nd noteworthy acceptance of the technique in pharmaceutical research.
10 c studies on catalyst formation processes in pharmaceutical research.
11  as isosteres of purine, are of interest for pharmaceutical research.
12 RF) peptide family is an important target in pharmaceutical research.
13  a number of applications in diagnostics and pharmaceutical research.
14 nostic genes, and thus are prime targets for pharmaceutical research.
15 ing diseases, they represent key targets for pharmaceutical research.
16  the potential to complement such methods in pharmaceutical research.
17    Moreover, the marked increase in clinical pharmaceutical research addressing SCD and the new and o
18 power of multiplatform MSI analysis within a pharmaceutical research and development (R&D) environmen
19     Genomics will succeed in revolutionising pharmaceutical research and development only if these in
20              Despite increased investment in pharmaceutical research and development, fewer and fewer
21 minishing marginal returns of investments in pharmaceutical research and development.
22 f so-called 'transgenic' mouse technology in pharmaceutical research and development.
23  could have a substantial negative effect on pharmaceutical research and development.
24 German Federal Ministry of Health and by the Pharmaceutical Research and Manufacturers Association of
25 red by the Food and Drug Administration, the Pharmaceutical Research and Manufacturers Association, a
26 lites in Safety Testing) committee of PhRMA (Pharmaceutical Research and Manufacturers of America) ha
27 ewable resources, with a potential impact on pharmaceutical research and molecular design and deliver
28 alized enantioenriched amines of interest in pharmaceutical research and other areas.
29 functionalized amine products of utility for pharmaceutical research and other areas.
30 n for in vivo applications is a milestone in pharmaceutical research and protein-drug development.
31 tions of drug effects in humans will advance pharmaceutical research and speed up clinical trials.
32 ful tools for high-throughput biomedical and pharmaceutical research and the advancement of proteomic
33  show great promise for basic biomedical and pharmaceutical research, and robust and portable point-o
34 the focus of a significant amount of current pharmaceutical research because they play a key role in
35 he fundamental basis for molecular design in pharmaceutical research, biocatalysis, and agrochemical
36        Of great interest to the academic and pharmaceutical research communities, helical transmembra
37 , Inc., Cambridge, MA, and Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan,
38                    We review four domains of pharmaceutical research: drug discovery and delivery, dr
39      Caveolin-1 is a target for academic and pharmaceutical research due to its many cellular roles a
40          PARs have been the subject of major pharmaceutical research efforts but the discovery of sma
41 receptors (GPCRs) have been a major focus of pharmaceutical research for many years.
42                                    Antisense pharmaceutical research has sought to provide drugs that
43 osteric modulators, an active area of modern pharmaceutical research, has proved challenging because
44 is under development at Bristol-Myers Squibb Pharmaceutical Research Institute for the treatment of h
45 Dr. Nicholas Dracopoli (Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ).
46 uestion mark4-HPR, Fenretinide; R.W. Johnson Pharmaceutical Research Institute, Springhouse, PA) and
47 rmacogenomics, DNA microarrays, etc.) drives pharmaceutical research into individual diseases of old
48                         The challenge facing pharmaceutical research is one of effective integration
49                             Despite years of pharmaceutical research, limited clinical success has be
50 n's disease has been an effective target for pharmaceutical research over the past four decades.
51 ort processes remains a serious challenge in pharmaceutical research, particularly the transport of u
52 y and directed evolution are central to many pharmaceutical research programs, yet the lack of robust
53                                              Pharmaceutical research requires pre-clinical testing of
54  natural 13C abundance; this matches typical pharmaceutical research settings in which ligand isotope
55 ties of obtaining isotope-labeled ligands in pharmaceutical research settings.
56  been identified as an attractive target for pharmaceutical research that is directed at the discover
57 Cancer cells have been increasingly grown in pharmaceutical research to understand tumorigenesis and
58 erivatives that are of potential interest to pharmaceutical research were synthesized within minutes

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。